‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated $10,000,000 for each of 
fiscal years 2026 through 2030, to remain available until 
expended, to the Director of the Institute to carry out this 
section.’’. 
(b) TRANSITION FOR THE GLIOBLASTOMA THERA-
PEUTICS NETWORK.—The Director of the National Can-
cer Institute shall take such steps as may be necessary 
for the orderly transition from the Glioblastoma Thera-
peutics Network carried out by the Director, as of the day 
before the date of enactment of this Act, to the research 
program authorized under section 417H of the Public 
Health Service Act, as added by subsection (a). In making 
such transition, the Director shall ensure that the pro-
gram authorized under such section 417H is based upon 
and consistent with the policies and procedures of the 
Glioblastoma Therapeutics Network carried out by the Di-
rector as of the day before the date of enactment of this 
Act. 
SEC. 5. CANCER CLINICAL TRIALS AND BIOMARKER TEST-
ING NATIONAL PUBLIC AWARENESS CAM-
PAIGN. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘SEC. 399V–8. CANCER CLINICAL TRIALS AND BIOMARKER 
TESTING 
NATIONAL 
PUBLIC 
AWARENESS 
CAMPAIGN. 
‘‘(a) NATIONAL CAMPAIGN.— 
‘‘(1) IN GENERAL.—The Secretary shall carry 
out a national campaign to increase the awareness 
and knowledge of health care providers and individ-
uals, including patients and caregivers, with respect 
to the importance of clinical trials in the treatment 
of cancer. 
‘‘(2) ACTIVITIES.— 
‘‘(A) IN GENERAL.—Activities under such 
national campaign shall include each of the fol-
lowing: 
‘‘(i) 
WRITTEN
MATERIALS.—Main-
taining a supply of written and digital ma-
terials that provide information to the pub-
lic on clinical trials, and distributing such 
materials to members of the public upon 
request. 
‘‘(ii) PUBLIC
SERVICE
ANNOUNCE-
MENTS; PUBLIC ENGAGEMENT.—Providing 
public service announcements, in accord-
ance with applicable law, including through 
publishing materials in digital or print 
form, and carrying out other public en-
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
gagement initiatives. Such public service 
announcements and other public engage-
ment initiatives shall include such an-
nouncements and initiatives intended to 
encourage individuals to discuss with their 
physicians— 
‘‘(I) what cancer clinical trials 
are; 
‘‘(II) the importance of clinical 
trials in the treatment of cancer; 
‘‘(III) how to enroll in cancer 
clinical trials; 
‘‘(IV) what cancer biomarker 
testing is; 
‘‘(V) the importance of biomarker 
testing in the diagnosis and treatment 
of cancer; and 
‘‘(VI) how to access cancer bio-
marker testing. 
‘‘(B) TARGETED POPULATIONS.—The Sec-
retary shall ensure that the national campaign 
includes communications, including public serv-
ice announcements and other public engage-
ment initiatives under subparagraph (A)(ii), 
that are— 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘(i) culturally and linguistically com-
petent; and 
‘‘(ii) targeted to— 
‘‘(I) specific populations that are 
at a higher risk of cancer, including 
such populations based on factors in-
cluding race, ethnicity, level of accul-
turation, and family history; 
‘‘(II) rural communities; and 
‘‘(III) such other communities as 
the Secretary determines appropriate. 
‘‘(3) CONSULTATION.—In carrying out the na-
tional campaign under this subsection, the Secretary 
shall consult with— 
‘‘(A) health care providers; 
‘‘(B) nonprofit organizations; 
‘‘(C) State and local public health depart-
ments; and 
‘‘(D) elementary and secondary schools 
and institutions of higher education. 
‘‘(b) DEMONSTRATION PROJECTS REGARDING OUT-
REACH AND EDUCATION STRATEGIES FOR CANCER AND 
BRAIN TUMOR PATIENTS.— 
‘‘(1) IN GENERAL.—The Secretary shall carry 
out a program to award grants or contracts to pub-
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
lic or nonprofit private entities for the purpose of 
carrying out demonstration projects to test, com-
pare, and evaluate different evidence-based outreach 
and education strategies to increase the awareness 
and knowledge of cancer and brain tumor clinical 
trials and biomarker testing. Such projects shall 
focus on the awareness and knowledge of patients 
(and the families of patients), physicians, nurses, 
and other key health professionals involved in brain 
tumor treatment. 
‘‘(2) AWARDS.—In making awards under para-
graph (1), the Secretary shall— 
‘‘(A) ensure that information provided 
through demonstration projects supported by 
such an award is consistent with the best avail-
able medical information; and 
‘‘(B) give preference to— 
‘‘(i) applicants with demonstrated ex-
pertise in— 
‘‘(I) biomarker testing and clin-
ical trials in brain tumors and other 
recalcitrant cancers; 
‘‘(II) brain cancer and other re-
calcitrant cancer education or treat-
ment; 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘(III) working with groups of pa-
tients and caregivers; and 
‘‘(IV) reaching geographic areas 
that have historically low rates of par-
ticipation in cancer clinical trials; and 
‘‘(ii) applicants that demonstrate in 
their application submitted under para-
graph (3) that the project for which they 
are seeking a grant or contract will involve 
and connect physicians, nurses, other key 
health professionals, health profession stu-
dents, hospitals, and payers. 
‘‘(3) APPLICATIONS.—To seek a grant or con-
tract under this subsection, an entity shall submit 
an application to the Secretary in such form, in such 
manner, and containing such agreements, assur-
ances, and information as the Secretary may reason-
ably require. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there is authorized 
to be appropriated $10,000,000 for the period of fiscal 
years 2026 through 2030.’’. 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
SEC. 6. PILOT PROGRAMS TO DEVELOP, STUDY, OR EVALU-
ATE APPROACHES TO MONITORING AND CAR-
ING FOR BRAIN TUMOR SURVIVORS. 
Part B of title IV of the Public Health Service Act 
(42 U.S.C. 284 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 409K. PILOT PROGRAMS TO DEVELOP, STUDY, OR 
EVALUATE APPROACHES TO MONITORING 
AND CARING FOR BRAIN TUMOR SURVIVORS. 
‘‘(a) IN GENERAL.—The Director of NIH may, as 
appropriate, make awards to eligible entities to establish 
pilot programs to develop, study, or evaluate approaches, 
including primary and specialty care, for monitoring and 
caring for adult and pediatric brain tumor survivors 
throughout their lifespan, including evaluating models for 
transition to post-treatment care and care coordination. 
‘‘(b) AWARDS.— 
‘‘(1) ELIGIBLE ENTITIES.— 
‘‘(A) IN GENERAL.—For purposes of this 
section, an eligible entity is— 
‘‘(i) a medical school; 
‘‘(ii) a children’s hospital; 
‘‘(iii) a cancer center; 
‘‘(iv) a community-based medical facil-
ity; or 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘(v) any other entity with significant 
experience and expertise in carrying out 
the activities described in subsection (a). 
‘‘(B) TYPES OF ENTITIES.—Awards under 
this section shall be made, to the extent prac-
tical, to— 
‘‘(i) small, medium, and large-sized el-
igible entities; and 
‘‘(ii) sites located in different geo-
graphic areas, including rural and urban 
areas. 
‘‘(2) PEER REVIEW.—In making awards under 
this section, the Director of NIH shall comply with 
the peer review requirements in section 492. 
‘‘(3) USE
OF
FUNDS.—Funds from awards 
under this section may be used to develop, study, or 
evaluate one or more models for monitoring and car-
ing for brain tumor survivors, which may include— 
‘‘(A) evaluating follow-up care, educational 
accommodations, monitoring, and other survi-
vorship programs (including peer support and 
mentoring programs); 
‘‘(B) developing and evaluating models for 
providing multidisciplinary care; 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘(C) disseminating information to health 
care providers about culturally and linguistically 
appropriate follow-up care for brain tumor sur-
vivors and their families, as appropriate and 
practicable; 
‘‘(D) developing and evaluating existing 
psychosocial evaluations, counseling, and sup-
port programs to improve the quality of life of 
brain tumor survivors and their families, which 
may include peer support and mentoring pro-
grams; 
‘‘(E) designing and evaluating tools, which 
may include tools generated by artificial intel-
ligence and machine learning, to support the se-
cure electronic transfer of treatment informa-
tion and care summaries from brain tumor care 
providers to other health care providers (includ-
ing primary and specialty care providers), which 
information and care summaries shall include 
risk factors and a plan for recommended follow- 
up care; 
‘‘(F) developing and evaluating initiatives 
that promote the coordination and effective 
transition of care between brain tumor care 
providers, primary and specialty care providers, 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
mental health professionals, and other health 
care professionals, as appropriate, including 
models that use a team-based or multi-discipli-
nary approach to care; and 
‘‘(G) disseminating information described 
in subparagraphs (A) through (F), including 
with respect to models, evaluations, programs, 
systems, and initiatives described in such sub-
paragraphs, to other health care providers (in-
cluding primary and specialty care providers) 
and to pediatric brain tumor survivors and their 
families, where appropriate and in accordance 
with Federal and State law. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
$5,000,000 for each of fiscal years 2026 through 2030.’’. 
SEC. 7. FDA GUIDANCE TO ENSURE BRAIN TUMOR PATIENT 
ACCESS TO CLINICAL TRIALS. 
Not later than 1 year after the date of enactment 
of this Act, the Secretary of Health and Human Services, 
acting through the Commissioner of Food and Drugs, 
shall issue guidance to help identify ways to minimize the 
potential for the exclusion of brain tumor patients and pa-
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
tients with rare and recalcitrant cancers from clinical 
trials evaluating treatments for other indications. 
Æ 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00018
Fmt 6652
Sfmt 6301
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB